Last reviewed · How we verify
nsclc pd l1 post platinum
Approved treatments
Clinical guidelines
- FDA label — 2L
As a single agent for the treatment of adult patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-authorized test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA QLEX.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- nsclc pd l1 post platinum patent landscape — cliff calendar, originator estates, attackable patents
- nsclc pd l1 post platinum treatment landscape brief
- nsclc pd l1 post platinum treatment updates RSS
Frequently asked questions about nsclc pd l1 post platinum
What are the treatment guidelines for nsclc pd l1 post platinum?
FDA label publishes guidelines for nsclc pd l1 post platinum. 1 guideline references tracked.
Related
- Treatment landscape: nsclc pd l1 post platinum patent cliff · nsclc pd l1 post platinum CI report
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing